[12] Patent
[11] Patent No.:GC0009344  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141397
Date of the Decision to Grant the Patent:11/Dec/2018

[21] Application No.:GC 2013-26037

[22] Filing Date:18/12/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
21/12/2012
61/740,520

[72] Inventors:1- Noel Alan Weldon BAKERŲŒ2- Alpesh MISTRY

[73] Owner: AstraZeneca AB, SE -151, 85 , Sodertalje , Sweden

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/496, 9/16, 9/20, 9/46 (2006.01)

[56] Cited Documents:

-US 2008153812 A1 (BUTTAR DAVID [GB] ET AL) 26 June 2008
-WO 2012052757 A1 (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; BARRY SIMON THOMAS [GB];) 26 April 2012
 
Examiner: PH. Mohammad S. AlMousa

[54] PHARMACEUTICAL FORMULATION OF N-[5-[2-3,5-DIMETHOXYPHENYLETHYL]-2H-PYRAZOL-3-YL]-4-[3R,5S-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE
[57] Abstract: There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
No. of claims: 7     No. of figures: 5


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.